Craig M. Kessler

Craig M. Kessler

Auto-generated profile, based on publicly available information

Craig M. Kessler

Georgetown University, Washington, DC, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2010 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
PCPeter Collins
Peter Collins
FBFrancesco Baudo
Francesco Baudo
AHAngela Huth-Kühne
Angela Huth-Kühne
JIJørgen Ingerslev
Jørgen Ingerslev
CKCraig M Kessler
Craig M Kessler
HLHervé Lévesque
Hervé Lévesque
Acquired hemophilia A (AHA) is a rare bleeding disorder caused by an autoantibody to coagulation factor (F) VIII. It is characterized by soft tissue bleeding in patients without a personal or family history of bleeding. Bleeding is variable, ranging from acute, life-threatening hemorrhage, with 9-22% mortality, to mild bleeding that requires no treatment. AHA usually presents to clinicians without prior experience of the disease, therefore diagnosis is frequently delayed and bleeds under treated.

1 June 1996 in Bailliere's Clinical Haematology
Verified
Journal Article
Closed access
ACAlice J. Cohen
Alice J. Cohen
CKCraig M. Kessler
Craig M. Kessler

4 November 2022 in Platelets
Verified
Journal Article
Open access
NCNichola Cooper
Nichola Cooper
WGWaleed Ghanima
Waleed Ghanima
QHQuentin A Hill
Quentin A Hill
PNPhillip Lindsay Ross Nicolson
Phillip Lindsay Ross Nicolson
VMVadim Markovtsov
Vadim Markovtsov
CKCraig Kessler
Craig Kessler
Spleen tyrosine kinase (SYK) is an important regulatory molecule of signal transduction pathways involved in the pathogenesis of autoimmune diseases such as immune thrombocytopenia (ITP), and the SYK-signaling pathway has emerged as a potential target for the treatment of numerous diseases. The aim of this narrative review is to summarize the biological properties of SYK and its involvement in disease pathways, provide an update on SYK inhibitors in the treatment of ITP, and consider other potential applications. Fostamatinib, the only licensed SYK inhibitor to date, produces clinical response in ITP patients, including those who are refractory to other treatments. It appears to reduce the risk of thrombotic events and may therefore be a drug to consider for patients with an increased thrombotic risk. Encouraging results have also been obtained in the treatment of warm autoimmune hemolytic anemia. Several other SYK inhibitors have entered clinical trials for a range of indications, reflecting the ability of these drugs to affect multiple signaling pathways. SYK inhibitors have the potential to target several aspects of COVID-19 pathogenesis including thrombosis, without affecting normal hemostasis, and data from the first study of fostamatinib in COVID-19 are encouraging. It is hoped that ongoing trials in autoimmune indications other than ITP, as well as in hematological malignancies and other disorders, confirm the promise of SYK inhibitors. Immune thrombocytopenia (ITP) is an autoimmune disease that usually happens when your immune system mistakenly attacks and destroys platelets, which are cells that help blood to clot. Individuals with ITP can experience easy or excessive bruising and bleeding. Scientists have identified that an enzyme called spleen tyrosine kinase (SYK) is involved in numerous biological processes that are associated with the immune system response, inflammation, and some types of cancer in humans. Therefore, it has become a target for new drugs which inhibit the action of SYK. In this review article, the authors provide a summary of the biological properties and actions of SYK and its involvement in various diseases, discuss information about drugs that have been developed as SYK inhibitors for the treatment of ITP, and consider other potential uses for drugs that inhibit SYK. Although several drugs are being developed, the only SYK inhibitor that is currently available for the treatment of ITP is a drug called fostamatinib. In patients with ITP, including those who no longer respond to other treatments, fostamatinib has been shown to improve platelet counts and reduce bleeding events. Researchers are also currently investigating the use of drugs that inhibit SYK, including fostamatinib, for the potential treatment of other diseases associated with inflammation (e.g. rheumatoid arthritis, COVID-19), autoimmunity (e.g. warm autoimmune hemolytic anemia), and blood cancers (e.g. lymphoma, chronic lymphocytic leukemia, and acute myeloid leukemia).

17 December 2015 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
CKCraig M. Kessler
Craig M. Kessler
PKPaul Knöbl
Paul Knöbl

16 May 2008 in Haemophilia
Verified
Journal Article
Closed access
PDF file
PCP. Collins
P. Collins
UBU. Budde
U. Budde
JRJ. H. Rand
J. H. Rand
AFA. B. Federici
A. B. Federici
CKC. M. Kessler
C. M. Kessler

1 October 2016 in Blood Coagulation & Fibrinolysis
Verified
Journal Article
Open access
CKCraig M. Kessler
Craig M. Kessler
AMAlice D. Ma
Alice D. Ma
HAHamid A.B. Al-Mondhiry
Hamid A.B. Al-Mondhiry
RGRobert Z. Gut
Robert Z. Gut
DCDavid L. Cooper
David L. Cooper
The Hemostasis and Thrombosis Research Society (HTRS) Registry was used to monitor the postapproval use of recombinant factor VIIa. The objective of this manuscript is to provide key insights on the demographics of patients with acquired hemophilia in the HTRS Registry. Acquired hemophilia patient registration in HTRS captured age; sex; comorbidities and predisposing conditions; first bleeding location; laboratory parameters; exposure to blood products, factor, and bypassing agents; and initiation of immune suppression/tolerance therapy. Overall, 166 patients with acquired hemophilia were registered in HTRS (83 women, 73 men, median age 70 years); the majority were non-Hispanic whites (61.4%). The most common comorbidities were autoimmune disease (28.4%) and malignancy (14.5%). The most common first site of bleeding was subcutaneous (27.1%); this was more common in whites (29.1%) than blacks (12.5%) and in non-Hispanics (26.4%) than Hispanics (11.8%). Blood product exposure was reported for 33.1% of patients; the most commonly reported product was packed red blood cells (28%). Of the 57 patients with outcome data available for immune tolerance therapy, 26 patients (46%) reported successful treatment, 13 reported unsuccessful treatment (23%), and 18 (32%) were receiving active treatment at the time of registration. The HTRS Registry final analysis provides the only current comprehensive look at acquired hemophilia in the US population, including details on underlying autoimmune diseases and malignancies. Pertinent to recognition and diagnosis of the disease, subcutaneous bleeding as a presenting bleeding symptom was more common in white and non-Hispanic individuals.